Tesamorelin reduces visceral fat and improves metabolic parameters in HIV-infected patients

This clinical analysis, published by Takara Stanley, Julian Falutz, Steven Grinspoon and collaborators in Clinical Infectious Diseases, evaluated the relationship between tesamorelin-induced visceral fat reduction and improvement of metabolic parameters in HIV-infected patients with abdominal lipodystrophy. Tesamorelin is a synthetic GHRH analog with a trans-3-hexenoic acid modification that confers greater stability and potency compared to native GHRH.

The authors analyzed data from phase 3 trials, demonstrating that tesamorelin works by stimulating pulsatile growth hormone (GH) release from the anterior pituitary, promoting subsequent increases in circulating IGF-1 and activation of visceral lipolysis. Unlike direct GH administration, tesamorelin preserves the physiological regulation of the somatotropic axis, resulting in lower incidence of metabolic adverse effects.

• The analysis confirmed that reductions of 15-18% in visceral fat were associated with metabolic improvement
• There was improvement in lipid parameters, including triglycerides and cholesterol
• The impact on insulin resistance was neutral to slightly favorable
• Treatment discontinuation resulted in gradual re-accumulation of visceral fat

The authors concluded that tesamorelin represents a unique therapeutic option for HIV-associated lipodystrophy, with a well-established efficacy and safety profile. The study also discussed potential future applications of tesamorelin in other conditions associated with excess visceral fat, such as non-alcoholic fatty liver disease.